|
|
 |
|
Viewing report
|
|
|
|
U.S. Emerging Ovarian Cancer Therapeutics Markets
Frost & Sullivan, Jan 2002
High Relapse Rate Drives Demand for Expanded Treatment Options
Though chemotherapy is effective in achieving remission in most ovarian
cancer patients, remission often lasts less than two years. Further chemotherapy
provides only limited success. The high relapse rate in these patients will
continue to drive demand for a wider range of therapeutic options. With a
myriad of new products currently in development, this market is poised to
expand rapidly. Given the prevalence of this disease in the U.S., manufacturers
of effective treatments should see impressive gains over the forecast period.
This Frost & Sullivan study analyzes the markets for emerging ovarian cancer
therapeutics, including treatments for localized, metastatic, and
relapsed/refractory cancers. It presents incidence rates for each segment,
reviews existing products, and assesses the potential of products still in
development. By tracking pricing trends and by offering accurate revenue
forecasts, this study gives its users a comprehensive view of the field.
Lack of Clinical Trial Patients Delays Time to Market
With more than forty products in development, competition for suitable
clinical trial patients is fierce, says the study’s author. Patients do not typically
consider clinical trials until they have exhausted all other options. However,
many end-stage patients do not qualify for experimental treatments because
of their extensive history with other therapies.
Nevertheless, clinical trials remain crucial for the acceptance of new
therapies. Drug companies will remain challenged to overcome this significant
barrier to product commercialization, states the anaylst. This study evaluates
industry challenges and provides strategies to help your company surmount
obstacles that may lay ahead.
Patent Expirations and Immunotherapy Changing Market Dynamics
Over the next five years, patents will expire for a number of leading
chemotherapeutic drugs, opening the door for generic competition, says the
author. Although the introduction of generics will threaten revenues for
well-branded products, it will enable new market participants to profit from
established therapies.
Meanwhile, the increasing use of immunotherapy presents an important
prospect for drug makers. Immunotherapeutics will become part of standard
treatment protocol as complementary therapies that can help delay relapse,
prolong survival, and improve quality of life, says the author. By
highlighting new opportunities, this study will help you target the lucrative
areas for growth.
Additional Information
Market Participants
AltaRex, Inc.
ALZA Corp.
Antisoma plc
AstraZeneca Pharmaceuticals
AVAX Technologies, Inc.
Aventis Pharmaceuticals, Inc.
Bristol-Myers Squibb, Inc.
Celgene Corp.
Cytran, Inc.
Eli Lilly
Genaera Corp.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Guilford Pharmaceuticals, Inc.
InterMune Pharmaceuticals, Inc.
Intracel Corp.
Introgen Therapeutics, Inc.
ISIS Pharmaceuticals, Inc.
Johnson & Johnson
Medarex, Inc.
MGI Pharma, Inc.
Millenium Pharmaceuticals, Inc.
NeoPharm, Inc.
Novartis Oncology
Onyx Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc.
Pharmacia Corp.
Roche US Pharmaceuticals
Schering-Plough Corp.
Seattle Genetics, Inc.
SuperGen, Inc.
Telik, Inc.
Vertex Pharmaceuticals, Inc.
Aerospace
Auto ID
Biotech
Chemicals
Conferencing
Consumer
e-Business
Environment
Food
Healthcare
Internet Security
IT
Latin America
Medical Devices
Motors
Pharmaceuticals
Power
Sensors
Smart Cards
Technical Insights
Telecom Services
Transportation
Water
Wireless
Customers who bought this item also bought
Ovarian Cancer Therapeutics - Global Strategic Business Report
Emerging Therapies for Ovarian Cancer
Cancer Therapeutics Markets
Strategic Perspectives 2001: Ovarian Cancer - Overview of Current and New Developments
U.S. Emerging Cancer Therapeutics Markets
Stakeholder Opinions: Ovarian Cancer - Beyond Carboplatin and Paclitaxel
New Cancer Therapeutics: An Analysis Of Current And Emerging Markets
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
|
|
|
